- Markets
- Healthcare
- THEMISMED
THEMISMED
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Themis Medicare Gets Tax Demand Of 41.8 Million Rupees
Nov 19 (Reuters) - Themis Medicare Ltd THEM.NS:
RECEIVED TAX DEMAND OF 41.8 MILLION RUPEES
Source text: ID:nBSEW1vsV
Further company coverage: THEM.NS
(([email protected];))
Nov 19 (Reuters) - Themis Medicare Ltd THEM.NS:
RECEIVED TAX DEMAND OF 41.8 MILLION RUPEES
Source text: ID:nBSEW1vsV
Further company coverage: THEM.NS
(([email protected];))
Themis Medicare Announces Amalgamation Of Gujarat Themis Biosyn With Co
Nov 18 (Reuters) - Themis Medicare Ltd THEM.NS:
THEMIS MEDICARE LTD - AMALGAMATION OF GUJARAT THEMIS BIOSYN LIMITED WITH THEMIS MEDICARE
THEMIS MEDICARE- TML WILL ISSUE 118 SHARES FOR EVERY 100 SHARES HELD BY IN GTBL
Source text: ID:nBSE4r0y7D
Further company coverage: THEM.NS
(([email protected];))
Nov 18 (Reuters) - Themis Medicare Ltd THEM.NS:
THEMIS MEDICARE LTD - AMALGAMATION OF GUJARAT THEMIS BIOSYN LIMITED WITH THEMIS MEDICARE
THEMIS MEDICARE- TML WILL ISSUE 118 SHARES FOR EVERY 100 SHARES HELD BY IN GTBL
Source text: ID:nBSE4r0y7D
Further company coverage: THEM.NS
(([email protected];))
India's Themis Medicare hits record high on Q1 profit jump
** Shares of Themis Medicare THEM.NS rise as much as 10.1% to a record high of 272.35 rupees
** THEM stock marks sharpest intraday climb since Feb26
** The pharma company on Friday reported a 35.7% climb in its June-quarter consolidated net profit of 246.8 mln rupees ($2.95 mln)
** "Consolidation in manpower in Active Pharmaceutical Ingredients(API) business and improved operational efficiencies led to higher margins," Managing Director Sachin Patel says
** More than 326,000 shares change hands, 3.2X the 30-day avg
** Stock last up 5.8%, taking YTD gains to 22.6%
($1 = 83.7150 Indian rupees)
(Reporting by Anisha Ajith in Bengaluru)
(([email protected];))
** Shares of Themis Medicare THEM.NS rise as much as 10.1% to a record high of 272.35 rupees
** THEM stock marks sharpest intraday climb since Feb26
** The pharma company on Friday reported a 35.7% climb in its June-quarter consolidated net profit of 246.8 mln rupees ($2.95 mln)
** "Consolidation in manpower in Active Pharmaceutical Ingredients(API) business and improved operational efficiencies led to higher margins," Managing Director Sachin Patel says
** More than 326,000 shares change hands, 3.2X the 30-day avg
** Stock last up 5.8%, taking YTD gains to 22.6%
($1 = 83.7150 Indian rupees)
(Reporting by Anisha Ajith in Bengaluru)
(([email protected];))
Themis Medicare June-Qtr Consol Net Profit 246.8 Mln Rupees
July 26 (Reuters) - Themis Medicare Ltd THEM.NS:
THEMIS MEDICARE JUNE-QUARTER CONSOL NET PROFIT 246.8 MILLION RUPEES
THEMIS MEDICARE JUNE-QUARTER CONSOL NET REVENUE FROM OPERATIONS 1.23 BILLION RUPEES
Source text for Eikon: ID:nBSEFyMDh
Further company coverage: THEM.NS
(([email protected];;))
July 26 (Reuters) - Themis Medicare Ltd THEM.NS:
THEMIS MEDICARE JUNE-QUARTER CONSOL NET PROFIT 246.8 MILLION RUPEES
THEMIS MEDICARE JUNE-QUARTER CONSOL NET REVENUE FROM OPERATIONS 1.23 BILLION RUPEES
Source text for Eikon: ID:nBSEFyMDh
Further company coverage: THEM.NS
(([email protected];;))
India's Themis Medicare hits record high
** Shares of pharmaceutical firm Themis Medicare THEM.NS up 8.5% to a record high of 234 rupees
** The reason for the move was not immediately clear
** Stock above 200- day moving avg since Nov. 9, 2023
** More than 347,000 shares traded, 1.6x the 30-day avg
** In Q3, stock was up for the fourth straight quarter
** THEM climbed ~58% in 2023, its fourth straight year of gains
(Reporting by Aleef Jahan in Bengaluru)
** Shares of pharmaceutical firm Themis Medicare THEM.NS up 8.5% to a record high of 234 rupees
** The reason for the move was not immediately clear
** Stock above 200- day moving avg since Nov. 9, 2023
** More than 347,000 shares traded, 1.6x the 30-day avg
** In Q3, stock was up for the fourth straight quarter
** THEM climbed ~58% in 2023, its fourth straight year of gains
(Reporting by Aleef Jahan in Bengaluru)
Themis Medicare To Consider Sub-Division Of Shares
May 4 (Reuters) - Themis Medicare Ltd THEM.NS:
TO CONSIDER SUB-DIVISION OF SHARES
Source text for Eikon: ID:nBSE20GvPH
Further company coverage: THEM.NS
(([email protected];))
May 4 (Reuters) - Themis Medicare Ltd THEM.NS:
TO CONSIDER SUB-DIVISION OF SHARES
Source text for Eikon: ID:nBSE20GvPH
Further company coverage: THEM.NS
(([email protected];))
Events:
Dividend
Split
Dividend
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Themis Medicare do?
Themis Medicare Ltd. is a research-based pharmaceutical company focusing on Pain Management, Critical Care, and Anti-Infectives. It develops differentiated products for patient benefit.
Who are the competitors of Themis Medicare?
Themis Medicare major competitors are Shree Ganesh Remed., Kopran, Hester Biosciences, NGL Fine-Chem, SMS Pharmaceuticals, Bajaj Healthcare, Nectar Lifesciences. Market Cap of Themis Medicare is ₹1,270 Crs. While the median market cap of its peers are ₹985 Crs.
Is Themis Medicare financially stable compared to its competitors?
Themis Medicare seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Themis Medicare pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Themis Medicare latest dividend payout ratio is 10.57% and 3yr average dividend payout ratio is 8.32%
How has Themis Medicare allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Themis Medicare balance sheet?
Balance sheet of Themis Medicare is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Themis Medicare improving?
No, profit is decreasing. The profit of Themis Medicare is ₹34.73 Crs for TTM, ₹43.52 Crs for Mar 2024 and ₹56.9 Crs for Mar 2023.
Is the debt of Themis Medicare increasing or decreasing?
Yes, The debt of Themis Medicare is increasing. Latest debt of Themis Medicare is ₹63.85 Crs as of Sep-24. This is greater than Mar-24 when it was ₹57.23 Crs.
Is Themis Medicare stock expensive?
Yes, Themis Medicare is expensive. Latest PE of Themis Medicare is 27.53, while 3 year average PE is 24.83. Also latest EV/EBITDA of Themis Medicare is 20.8 while 3yr average is 20.67.
Has the share price of Themis Medicare grown faster than its competition?
Themis Medicare has given lower returns compared to its competitors. Themis Medicare has grown at ~14.1% over the last 7yrs while peers have grown at a median rate of 15.52%
Is the promoter bullish about Themis Medicare?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Themis Medicare is 67.15% and last quarter promoter holding is 67.15%.
Are mutual funds buying/selling Themis Medicare?
There is Insufficient data to gauge this.